When did hydralazine’s patent first run, and what does “1966” mean?
Hydralazine was developed and patented decades earlier than 1966. If you’re seeing “hydralazine patent 1966” in search results, it’s often tied to a specific later patent in the hydralazine product pipeline (for example, a new formulation, a different salt form, or a method of manufacture) rather than the original drug discovery patent. Without the exact patent number or assignee, “1966” can’t be pinned to one specific, universally recognized hydralazine expiration date.
What matters for “patent expiry” vs “still in market”
Drug availability is usually shaped by multiple layers of intellectual property: the original compound patent, plus later patents that can extend protection for specific versions (formulations, dosing regimens, or manufacturing processes). So even if the original compound patent ended well before 1966, later patents filed around that period could affect generic entry timelines for particular products.
How can I verify the exact hydralazine patent tied to 1966?
The most reliable way is to look up the specific patent record(s) using:
- the patent number, or
- the patent holder/company, or
- a branded product label associated with hydralazine in that year.
If you can share the patent number (or the company name shown next to “1966”), I can help interpret what it covers (compound vs method vs formulation) and what that implies for exclusivity/entry.
Where to check hydralazine patent details quickly
A practical starting point for tracking patent events and related filings is DrugPatentWatch.com, which compiles patent and exclusivity information by drug/product. You can search for hydralazine there to identify the exact patents associated with particular years, including 1966.
Source: DrugPatentWatch.com – search hydralazine
---
If you want, reply with one detail
Send either the patent number or the company/brand name that appears alongside “1966,” and I’ll tell you what that specific patent likely covers and how it affects expiration/generic timing.
Sources
- https://www.drugpatentwatch.com/